GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Operating Margin %
Switch to:

Biogen (MEX:BIIB) Operating Margin %

: 21.00% (As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Biogen's Operating Income for the three months ended in Mar. 2023 was MXN9,324 Mil. Biogen's Revenue for the three months ended in Mar. 2023 was MXN44,396 Mil. Therefore, Biogen's Operating Margin % for the quarter that ended in Mar. 2023 was 21.00%.

Warning Sign:

Biogen Inc operating margin has been in a 5-year decline. The average rate of decline per year is -11.7%.

The historical rank and industry rank for Biogen's Operating Margin % or its related term are showing as below:

MEX:BIIB' s Operating Margin % Range Over the Past 10 Years
Min: 25.57   Med: 42.49   Max: 49.39
Current: 27.49


MEX:BIIB's Operating Margin % is ranked better than
93.26% of 1038 companies
in the Drug Manufacturers industry
Industry Median: 4.90 vs MEX:BIIB: 27.49

Biogen's 5-Year Average Operating Margin % Growth Rate was -11.70% per year.

Biogen's Operating Income for the three months ended in Mar. 2023 was MXN9,324 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2023 was MXN54,464 Mil.


Biogen Operating Margin % Historical Data

The historical data trend for Biogen's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.61 48.93 33.07 25.57 28.52

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.35 35.03 32.88 20.77 21.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Operating Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Biogen's Operating Margin % falls in comparison to its industry or sector. The grey bar indicates the Operating Margin %'s extreme value range as defined by GuruFocus.



Biogen Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Biogen's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=56575.442 / 198340.607
=28.52 %

Biogen's Operating Margin % for the quarter that ended in Mar. 2023 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2023 ) / Revenue (Q: Mar. 2023 )
=9324.332 / 44395.575
=21.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Biogen Operating Margin % Related Terms

Thank you for viewing the detailed overview of Biogen's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines

Other Sources

12 Cheap Biotech Stocks To Buy

By Yahoo Finance 2023-01-25